Platelet-derived exosomes as the nano-carrier for miR-150 to modulate gene expression and cell cycle in the M07-e cell line

• Published in: Journal of drug delivery science and technology Vol. 86; p. 104644
• Main Authors: Shams, Seyyede Fatemeh, Mohammadipour, Mahshid, Deyhim, Mohammad Reza
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.09.2023
• Subjects: Cargo loading; Extracellular vesicles; Genes; miRNA delivery; Extracellular vesicles; miRNA delivery; Cargo loading; Genes
• ISSN: 1773-2247
• DOI: 10.1016/j.jddst.2023.104644

Platelet-derived exosomes are the most abundant Nano-particles in the plasma of healthy individuals. They have been wildly used as drugs, vectors, and miRs carriers. The present study was designed to hope its results will be used to treat patients with refractory thrombocytopenia. To follow the study's aims, we examined the capacity of platelet-derived exosomes to carry miR-150 and their influence on the expression of c-myb (the target gene of miR-150) and mitosis induction in the megakaryocytic model of M07-e. In this experimental study, platelets were obtained via the platelet concentrates (PCs) prepared by the platelet-rich plasma (PRP) method. Then the exosomes were isolated from the platelets by the isolation kit. The isolated particles were loaded with miR-150 through the modified CaCl2 method. The efficiency of the transfection process was evaluated via qRT-PCR. The effect of loaded exosomes on the gene expression profile (c-myb) and the cell cycle of the megakaryocytic model (M07-e) was assessed via qRT-PCR and flow cytometry methods. Exosomes successfully mediated miR-150 transfer into the cells. As a result, they down modulated c-myb expression significantly (p-value ≤0.05). It means miRs were successfully transferred and did not lose their function; on the other hand, they could not induce cell cycle transition. The findings of the present study shed light on the development of autologous Nano-carriers, which could be a step in advancing the aims of personalized medicine and reducing the side effects of the exogenous carrier. [Display omitted]